Tildrakizumab in Psoriatic Patients With Current or Past Malignancy: A Real‐Life Cohort and Literature Review
International Journal of Dermatology · 2026-02 · 65 (2) · 281-288
DOI: 10.1111/ijd.70053 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift International Journal of Dermatology, online erschienen am 10.09.2025. Verfasst von Ofelia Baniandrés und 32 weiteren Autor:innen. Beteiligte Einrichtung: Servicio de Dermatología, Hospital General Universitario Gregorio Marañón, Madrid, Spain. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Neoplasms, Psoriasis. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 45 Literaturangaben.
Abstract (Originalsprache)
Background
Tildrakizumab has demonstrated high efficacy and a good long‐term safety profile, including low malignancy rates, in Phase III trials with 5‐year extension. Despite these data, the real‐world evidence on patients with psoriasis and a history of cancer is limited.
Objectives
To assess the efficacy and safety of tildrakizumab in a cohort of patients with moderate‐to‐severe psoriasis and a previous or current history of neoplasia.
Methods
We conducted a retrospective, observational, multicentre study across 27 Spanish dermatology departments. All patients had moderate‐to‐severe plaque psoriasis and a prior history of an active neoplasia at the time of initiating tildrakizumab treatment.
Results
Forty‐eight patients with a mean follow‐up period of 50 weeks after initiation of tildrakizumab were included. At Week 24, 82.4% of evaluable patients achieved a Psoriasis Area and Severity Index (PASI) score < 3. By Week 48, 80.0% achieved PASI < 1 and 50.0% reached PASI 0. Twelve patients (25%) began treatment within one year of cancer diagnosis, and four patients started tildrakizumab prior to cancer detection and did not stop treatment. Of the remaining 32, they started tildrakizumab an average of 4.95 years after the cancer diagnosis. Seven patients had active neoplasia at baseline. Overall, 95.8% of the patients did not experience recurrence or worsening of the neoplasia. No adverse events related to tildrakizumab were reported. The cancer state was not considered affected by the psoriasis therapy in any of the cases.
Conclusion
The treatment of moderate to severe psoriasis with tildrakizumab was an effective option, with a safe profile in patients with a history of cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Servicio de Dermatología, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
- Servicio de Dermatología, Hospital General Universitario de Castellón, Castellon de la Plana, Spain.
- Servicio de Dermatología, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
- Servicio de Dermatología, Hospital Severo Ochoa, Leganés, Spain.
- Servicio de Dermatología, Hospital Universitario La Paz, Madrid, Spain.
- Servicio Dermatología, Hospital Doctor Peset, Valencia, Spain.
ORCID-Profile: Ofelia Baniandrés, Inmaculada Balaguer Franch, Eva Vilarrasa Rull, María Luisa Alonso Pacheco, Adrián Ballano Ruiz, Álvaro González Cantero, Elena Martínez Lorenzo, Manuel Galán Gutiérrez, Aina Vila Payeras, Marcial Álvarez Salafranca, Isabel Martínez Pallas, Constantin Luca Schneller-Pavelescu Apetrei, Juan Monte Serrano, Leandra Reguero Del Cura, Pablo de la Cueva Dobao
Zitieren
APA
Baniandrés, O., Balaguer Franch, I., Vilarrasa Rull, E., Imbernón Moya, A., Alonso Pacheco, M. L., Mateu Puchades, A., Hergueta Sánchez, J. P., Mataix Díaz, F. J., Ballano Ruiz, A., González Cantero, Á., Martínez Lorenzo, E., Galán Gutiérrez, M., Rodríguez Fernández-Freire, L., Vila Payeras, A., Muñoz Santos, C., Hernández Bel, P., Hernández Ostiz, S., Pujol Montcusí, J., Álvarez Salafranca, M., …, & de la Cueva Dobao, P. (2026). Tildrakizumab in Psoriatic Patients With Current or Past Malignancy: A Real‐Life Cohort and Literature Review. International Journal of Dermatology, 65(2), 281-288. https://doi.org/10.1111/ijd.70053
Vancouver
Baniandrés O, Balaguer Franch I, Vilarrasa Rull E, Imbernón Moya A, Alonso Pacheco ML, Mateu Puchades A, et al. Tildrakizumab in Psoriatic Patients With Current or Past Malignancy: A Real‐Life Cohort and Literature Review. International Journal of Dermatology. 2026;65(2):281-288. doi:10.1111/ijd.70053
BibTeX
@article{Baniandrs2026,
author = {Baniandrés, Ofelia and Balaguer Franch, Inmaculada and Vilarrasa Rull, Eva and Imbernón Moya, Adrián and Alonso Pacheco, María Luisa and Mateu Puchades, Almudena and Hergueta Sánchez, Julia Paloma and Mataix Díaz, Francisco Javier and Ballano Ruiz, Adrián and González Cantero, Álvaro and Martínez Lorenzo, Elena and Galán Gutiérrez, Manuel and Rodríguez Fernández-Freire, Lourdes and Vila Payeras, Aina and Muñoz Santos, Carlos and Hernández Bel, Pablo and Hernández Ostiz, Sergio and Pujol Montcusí, Josep and Álvarez Salafranca, Marcial and Coto Segura, Pablo and Martínez Pallas, Isabel and Azón Masoliver, Antoni and Martínez Manchón, Teresa and Delgado Mucientes, Carmen and Schneller-Pavelescu Apetrei, Constantin Luca and Ballester Martínez, Asunción and Monte Serrano, Juan and Pindado Ortega, Cristina and Reguero Del Cura, Leandra and López Barragán, Irene and Chavarría Mur, Eva and González Olivares, Mónica and de la Cueva Dobao, Pablo},
title = {Tildrakizumab in Psoriatic Patients With Current or Past Malignancy: A Real‐Life Cohort and Literature Review},
journal = {International Journal of Dermatology},
year = {2026},
volume = {65},
number = {2},
pages = {281--288},
doi = {10.1111/ijd.70053}
}
EUVIMED